Allied Market Research
Loading...
0
New
New
2021
Telemedicine Market

Telemedicine market by Application (Teleradiology, Telepsychiatry, Telepathology, Teledermatology, Telecardiology and Other Applications), Component (Software, Hardware and Services), and End User (Healthcare Providers, Payers, Healthcare Consumers and Other End Users): Global Opportunity Analysis and Industry Forecast, 2021–2030

A00412
Pages: 244
Jul 2021 | 5874 Views
   
Author(s) : Apoorva Srivastava , Onkar Sumant
Tables: 130
Charts: 43
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Telemedicine Market

Request Now !

The global telemedicine market was valued at $40,205.68 million in 2020, and is estimated to reach $431,823.81 million by 2030, growing at a CAGR of 25.90% from 2021 to 2030. Telemedicine, also referred to as telehealth or e-medicine, is the remote delivery of healthcare services, including exams and consultations, over the telecommunications infrastructure. Telemedicine allows healthcare providers to evaluate, diagnose and treat patients without the need for an in-person visit.  

COVID-19 has positively impacted growth of the global telemedicine market. In addition, the postponement and cancellation of elective surgeries and appointments have decreased patient volume in hospitals and clinics. This poses an urgent need for physicians to adopt telehealth to connect to their patients and boost the market growth.

Telemedicine-Market-2021-2030

Get more information on this report : Request Sample Pages

The demand for healthcare services and technologies reached an all-time high in the wake of the pandemic. Furthermore, technologies such as telemedicine, chatbots, and others, are being deployed to help gather information, reassure the population, treat patients, and make diagnoses. Moreover, some countries are investing in innovative digital and telecommunication solutions to connect physicians remotely. Thus, it is expected to create a positive impact during the forecast period.

Increase in demand for radiological services owing to high prevalence of chronic diseases such as congestive heart failure, orthopedic injuries and others are the major factors that propel the growth of the telemedicine market. In addition, significant increase in government expenditure on healthcare information (HCIT) sector and rise in focus of key players toward bringing innovation to digital diagnostics further fuels the market growth. Moreover, continuous advancements in medical diagnostic technologies are expected to provide lucrative opportunities for the growth of the telemedicine market during the forecast years.

In addition, the rise in the developing prospects in the developed countries will further provide potential opportunities for the growth of the telemedicine market in the forecast years. The rapid advancements in healthcare and the high demand of virtual consultation by physicians and patients will further accelerate the expansion of the telemedicine market and are also offering significant growth opportunities for the market during the forecast period

In addition to that, the widespread presence of cancer, the increasing workload of healthcare providers, and advances in laboratory diagnostic tests drives the growth of telemedicine market globally. However, the high initial setup cost and error in sampling pathological data would be catastrophic for global telemedicine market.

Telemedicine market by Application
By Application

Your browser does not support the canvas element.

Teledermatology segment holds the dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Growth in the telemedicine market is mainly driven by factors such as rise in population, the need to expand healthcare access, increase in prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, government support, surge in awareness, and increase in technology adoption during the COVID-19 pandemic. However, regional variations in regulations, fraud, and the use of social media for care provision will impede market growth.

Telemedicine Market Segmentation

The telemedicine market is segmented on the basis of application, component, end user and region. By application, the market is categorized into teleradiology, telepsychiatry, telepathology, teledermatology, telecardiology & other applications. By component, the market is divided into software, hardware & services. By end user, it is fragmented into healthcare providers, payers, healthcare consumers & other end users. 

Telemedicine market by Application
By Component

Your browser does not support the canvas element.

Software segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment review

Depending on application, the teledermatology segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period. This is attributed to the rising incidence of skin diseases is also contributing to the teledermatology market growth. On the basis of component, the software segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period. This is attributed to increasing adoption of telehealth and telemedicine. 

Telemedicine market by Application
By End user

Your browser does not support the canvas element.

Healthcare Providers segment holds the dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

North America accounted for a major share in the telemedicine market in 2020, and is expected to maintain its dominance during the forecast period, due to rising healthcare awareness coupled with cloud-based technologies acceptance over the forecast years. Furthermore, a developed region such as North America, has accounted for the maximum revenue share in the global industry due to constant R&D initiatives. Moreover, presence of major players operating in the region fuel the growth of the market. However, Asia-Pacific is expected to register highest CAGR from 2021 to 2030, owing to rapid demand for healthcare assistance, especially in the rural area. Furthermore, innovation and development toward telecommunication are anticipated to further fuel the growth in this region in the near future. 

The key players operating in the global market include Koninklijke Philips N.V., Medtronic, GE Healthcare, Cerner Corporation, Siemens Healthineers, Cisco Systems, Inc., Teladoc Health Inc., American Well, AMC Health, and MDLive.

Telemedicine market by Application
By Region

2030
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 29.00% during 2021-2030

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the telemedicine market, and the current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Key Market Segments

By Application

  • Teleradiology
  • Telepsychiatry
  • Telepathology
  • Teledermatology
  • Telecardiology
  • Other Applications 

By Component

  • Software
  • Hardware
  • Services

By End User

  • Healthcare Providers
    • Software
    • Hardware
    • Services
  • Payers
    • Software
    • Hardware
    • Services
  • Healthcare Consumers
    • Software
    • Hardware
    • Services
  • Other End Users
    • Software
    • Hardware
    • Services

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players 

  • Koninklijke Philips N.V. 
  • Medtronic 
  • GE Healthcare
  • Cerner Corporation
  • Siemens Healthineers
  • Cisco Systems, Inc.
  • Teladoc Health Inc.
  • American Well 
  • AMC Health
  • MDLive
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in government investments and R&D expenditure in pharmaceutical & biotechnology companies
3.5.1.2.Surge in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
3.5.1.3.Rise in demand for high end customized oligos and upgradation in purification

3.5.2.Restraints

3.5.2.1.Complexities associated with therapeutic oligos
3.5.2.2.Challenging delivery of oligonucleotide drugs to specific targets

3.5.3.Opportunities

3.5.3.1.Growth opportunities in emerging economies
3.5.3.2.Growing focus on personalized medicine

3.5.4.Impact analysis

3.6.COVID-19 impact analysis on the oligonucleotide synthesis market

CHAPTER 4:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Oligonucleotide-based drugs

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Synthesized oligonucleotides

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Reagents

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

4.5.Equipment

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country

CHAPTER 5:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Therapeutic applications

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by Product

5.3.Research applications

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by Product

5.4.Diagnostic applications

5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by Product

CHAPTER 6:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Pharmaceutical & biotechnology companies

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Diagnostic laboratories

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

6.5.CROs and CMOs

6.5.1.Market size and forecast
6.5.2.Market analysis, by country

6.6.Academic research institutes

6.6.1.Market size and forecast
6.6.2.Market analysis, by country

CHAPTER 7:OLIGONUCLEOTIDE SYNTHESIS, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. oligonucleotide synthesis market, by product
7.2.2.1.2.U.S. oligonucleotide synthesis market, by application
7.2.2.1.3.U.S. oligonucleotide synthesis market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada oligonucleotide synthesis, by product
7.2.2.2.2.Canada oligonucleotide synthesis market, by application
7.2.2.2.3.Canada oligonucleotide synthesis market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico oligonucleotide synthesis market, by product
7.2.2.3.2.Mexico oligonucleotide synthesis market, by application
7.2.2.3.3.Mexico oligonucleotide synthesis market, by end user

7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany oligonucleotide synthesis market, by product
7.3.2.1.2.Germany oligonucleotide synthesis market, by application
7.3.2.1.3.Germany oligonucleotide synthesis market, by end user

7.3.2.2.France

7.3.2.2.1.France oligonucleotide synthesis market, by product
7.3.2.2.2.France oligonucleotide synthesis market, by application
7.3.2.2.3.France oligonucleotide synthesis market, by end user

7.3.2.3.UK

7.3.2.3.1.UK oligonucleotide synthesis market, by product
7.3.2.3.2.UK oligonucleotide synthesis market, by application
7.3.2.3.3.UK oligonucleotide synthesis market, by end user

7.3.2.4.Italy

7.3.2.4.1.Italy oligonucleotide synthesis market, by product
7.3.2.4.2.Italy oligonucleotide synthesis market, by application
7.3.2.4.3.Italy oligonucleotide synthesis market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain oligonucleotide synthesis market, by product
7.3.2.5.2.Spain oligonucleotide synthesis market, by application
7.3.2.5.3.Spain oligonucleotide synthesis market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe oligonucleotide synthesis market, by product
7.3.2.6.2.Rest of Europe oligonucleotide synthesis market, by application
7.3.2.6.3.Rest of Europe oligonucleotide synthesis market, by end user

7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan Oligonucleotide synthesis market, by product
7.4.2.1.2.Japan oligonucleotide synthesis market, by application
7.4.2.1.3.Japan oligonucleotide synthesis market, by end user

7.4.2.2.China

7.4.2.2.1.China Oligonucleotide synthesis market, by product
7.4.2.2.2.China oligonucleotide synthesis market, by application
7.4.2.2.3.China Oligonucleotide synthesis market, by end user

7.4.2.3.Australia

7.4.2.3.1.Australia oligonucleotide synthesis market, by product
7.4.2.3.2.Australia oligonucleotide synthesis market, by application
7.4.2.3.3.Australia oligonucleotide synthesis market, by end user

7.4.2.4.India

7.4.2.4.1.India oligonucleotide synthesis market, by product
7.4.2.4.2.India oligonucleotide synthesis market, by application
7.4.2.4.3.India oligonucleotide synthesis market, by end user

7.4.2.5.South Korea

7.4.2.5.1.South Korea oligonucleotide synthesis market, by product
7.4.2.5.2.South Korea oligonucleotide synthesis market, by application
7.4.2.5.3.South Korea Oligonucleotide synthesis market, by end user

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific oligonucleotide synthesis market, by product
7.4.2.6.2.Rest of Asia-Pacific oligonucleotide synthesis market, by application
7.4.2.6.3.Rest of Asia-Pacific oligonucleotide synthesis market, by end user

7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil oligonucleotide synthesis market, by product
7.5.2.1.2.Brazil oligonucleotide synthesis market, by application
7.5.2.1.3.Brazil oligonucleotide synthesis market, by end user

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia oligonucleotide synthesis market, by product
7.5.2.2.2.Saudi Arabia oligonucleotide synthesis market, by application
7.5.2.2.3.Saudi Arabia oligonucleotide synthesis market, by end user

7.5.2.3.South Africa

7.5.2.3.1.South Africa oligonucleotide synthesis market, by product
7.5.2.3.2.South Africa oligonucleotide synthesis market, by application
7.5.2.3.3.South Africa oligonucleotide synthesis market, by end user

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA oligonucleotide synthesis market, by product
7.5.2.4.2.Rest of LAMEA oligonucleotide synthesis market, by application
7.5.2.4.3.Rest of LAMEA oligonucleotide synthesis market, by end user

7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ALNYLAM PHARMACEUTICALS, INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.BIOGEN LIMITED

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.CINVEN

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.DANAHER CORPORATION

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.EUROFINS SCIENTIFIC

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.IONIS PHARMACEUTICALS, INC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.KANEKA CORPORATION

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.MERCK KGAA

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SAREPTA THERAPEUTICS, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.THERMO FISHER SCIENTIFIC, INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030 ($BILLION)
TABLE 02.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020-2030 ($BILLION)
TABLE 03.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020-2030 ($BILLION)
TABLE 04.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020-2030 ($BILLION)
TABLE 05.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020-2030 ($BILLION)
TABLE 06.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030($BILLION)
TABLE 07.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 08.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 09.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 10.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 11.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2030($BILLION)
TABLE 12.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTICS APPLICATIONS, BY PRODUCT, 2020-2030($BILLION)
TABLE 13.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 14.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020-2030($MILLION)
TABLE 15.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2030($MILLION)
TABLE 16.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2030($MILLION)
TABLE 17.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY REGION, 2020-2030($MILLION)
TABLE 18.OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020-2030($MILLION)
TABLE 19.OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020-2030($MILLION)
TABLE 20.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 21.U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 22.U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 23.U.S. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 24.CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 25.CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 26.CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 27.MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 28.MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 29.MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 30.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 31.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET , BY APPLICATION, 2020-2030
TABLE 32.NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 33.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 34.GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 35.GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 36.GERMANY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 37.FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 38.FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 39.FRANCE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 40.UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 41.UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 42.UK OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 43.ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 44.ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 45.ITALY OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 46.SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 47.SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 48.SPAIN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 49.REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 50.REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 51.REST OF EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 52.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 53.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 54.EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 55.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 56.JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 57.JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 58.JAPAN OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 59.CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 60.CHINA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 61.CHINA OLIGONUCLEOTIDE SYNTHESIS, BY END USER, 2020-2030
TABLE 62.AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 63.AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 64.AUSTRALIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 65.INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 66.INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 67.INDIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 68.SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 69.SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 70.SOUTH KOREA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 71.REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 72.REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 73.REST OF ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 74.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 75.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 76.ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 77.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 78.BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 79.BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 80.BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 81.SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 82.SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 83.SAUDI ARABIA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 84.SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 85.SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 86.SOUTH AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 87.REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 88.REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 89.REST OF LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 90.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020-2030
TABLE 91.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020-2030
TABLE 92.LAMEA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020-2030
TABLE 93.ALNYLAM: COMPANY SNAPSHOT
TABLE 94.ALNYLAM: OPERATING BUSINESS SEGMENTS
TABLE 95.ALNYLAM: PRODUCT PORTFOLIO
TABLE 96.ALNYLAM: KEY DEVELOPMENTS
TABLE 97.BIOGEN: COMPANY SNAPSHOT
TABLE 98.BIOGEN: OPERATING SEGMENTS
TABLE 99.BIOGEN: PRODUCT PORTFOLIO
TABLE 100.BIOGEN: KEY DEVELOPMENTS
TABLE 101.CINVEN: COMPANY SNAPSHOT
TABLE 102.CINVEN: OPERATING SEGMENTS
TABLE 103.CINVEN: PRODUCT PORTFOLIO
TABLE 104.DANAHER: COMPANY SNAPSHOT
TABLE 105.DANAHER: PRODUCT SEGMENTS
TABLE 106.DANAHER: PRODUCT PORTFOLIO
TABLE 107.DANAHER: KEY DEVELOPMENTS
TABLE 108.EUROFINS: COMPANY SNAPSHOT
TABLE 109.EUROFINS: PRODUCT PORTFOLIO
TABLE 110.EUROFINS: KEY DEVELOPMENTS
TABLE 111.IONIS: COMPANY SNAPSHOT
TABLE 112.IONIS: OPERATING BUSINESS SEGMENTS
TABLE 113.IONIS: PRODUCT PORTFOLIO
TABLE 114.IONIS: KEY DEVELOPMENTS
TABLE 115.KANEKA: COMPANY SNAPSHOT
TABLE 116.KANEKA: OPERATING SEGMENTS
TABLE 117.KANEKA: PRODUCT PORTFOLIO
TABLE 118.KANEKA: KEY DEVELOPMENTS
TABLE 119.MERCK: COMPANY SNAPSHOT
TABLE 120.MERCK: OPERATING SEGMENTS
TABLE 121.MERCK: PRODUCT PORTFOLIO
TABLE 122.MERCK: KEY DEVELOPMENTS
TABLE 123.SAREPTA: COMPANY SNAPSHOT
TABLE 124.SAREPTA: OPERATING BUSINESS SEGMENTS
TABLE 125.SAREPTA: PRODUCT PORTFOLIO
TABLE 126.SAREPTA: KEY DEVELOPMENTS
TABLE 127.THERMO FISHER: COMPANY SNAPSHOT
TABLE 128.THERMO FISHER: OPERATING SEGMENTS
TABLE 129.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 130.THERMO FISHER: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020 & 2030 ($BILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY,  2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.ALNYLAM: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30.EUROFINS: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.EUROFINS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32.IONIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.KANEKA: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.KANEKA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.KANEKA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40.SAREPTA: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)

 
 

The telemedicine market gained prominence in 2020, and is expected to witness a significant rise in the near future. This is attributed to rise in incidence of chronic diseases, increase in adoption of telemedicine-based consultations during COVID-19, and surge in awareness toward the benefits of telemedicine services. However, regional variations in regulations, fraud, and use of social media for care provision will impede the market growth.

The rising demand for mobile technologies, rising adoption of home care by patients, and reduction in hospital visits are expected to propel the growth of the market in the forecast years. Furthermore, healthcare in the U.S. is experiencing positive trends, with the emergence of telemedicine applications that help Americans to be active in personal health management, especially during the current COVID-19 pandemic. Smartphones and the presence of mobile technology make it possible to use both clinical and lifestyle applications to help, educate, and change health behaviors.

Also, the initiatives by the government are expected to drive the market. For instance, the Centers for Medicare & Medicaid Services (CMS) has widened access to Medicare telehealth services due to which beneficiaries can get a wider range of services from healthcare professionals without having to travel to healthcare settings. In addition, Medicare will also pay for hospital, office, and other visits furnished via telehealth across the country, which also includes in patient’s places of residence started from March 6, 2020. This is expected to have a positive impact on the telemedicine market during the forecast years.

 

 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of telemedicine market is $40,205.68 million in 2020.

A. The forcast period for telemedicine market is 2021 to 2030

A. The market value of telemedicine market in 2030 is $431,823.81 million.

A. The base year is 2020 in telemedicine market

A. Top companies such as ,Koninklijke Philips N.V., Medtronic, GE Healthcare, Siemens Healthineers, Cerner Corporation held a high market position in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. In component software segment is the most influencing segment. This is attributed to increasing adoption of telehealth, telemedicine and telemedicine-based consultations during the COVID-19.

A. The major factor that fuels the growth of the global telemedicine market includes technological advancements & adoption in the wake of COVID-19, Significant Reduction in Healthcare Cost Burden to Boost Growth. However, Poor Infrastructure and Technological Barrier to Hinder Growth.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the emerging countries. This is due to to increase in health awareness, development in health care infrastructure, and rise in the adoption of virtual consultation.

A. Telemedicine involves the use of electronic communications and software to provide clinical services to patients without an in-person visit

A. teleradiology, telepsychiatry, telepathology, teledermatology, telecardiology & other applications

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Telemedicine Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers